|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
2
|
Conteduca V, Sansonno D, Ingravallo G,
Marangi S, Russi S, Lauletta G and Dammacco F: Barrett’s esophagus
and esophageal cancer: An overview. Int J Oncol. 41:414–424. 2012.
View Article : Google Scholar
|
|
3
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar
|
|
4
|
Berger AC, Farma J, Scott WJ, Freedman G,
Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to
neoadjuvant chemoradiotherapy in esophageal carcinoma is associated
with significantly improved survival. J Clin Oncol. 23:4330–4337.
2005. View Article : Google Scholar
|
|
5
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
6
|
Law S, Kwong DL, Kwok KF, Wong KH, Chu KM,
Sham JS and Wong J: Improvement in treatment results and long-term
survival of patients with esophageal cancer: Impact of
chemoradiation and change in treatment strategy. Ann Surg.
238:339–3488. 2003.
|
|
7
|
Sjoquist KM, Burmeister BH, Smithers BM,
Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian
Gastro-Intestinal Trials Group: Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal
carcinoma: An updated meta-analysis. Lancet Oncol. 12:681–692.
2011. View Article : Google Scholar
|
|
8
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar
|
|
9
|
Hong L, Han Y, Zhang H and Fan D:
Prognostic markers in esophageal cancer: From basic research to
clinical use. Expert Rev Gastroenterol Hepatol. 9:887–889. 2015.
View Article : Google Scholar
|
|
10
|
Haenisch S and Cascorbi I: miRNAs as
mediators of drug resistance. Epigenomics. 4:369–381. 2012.
View Article : Google Scholar
|
|
11
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar
|
|
12
|
Bartel DP: MicroRnAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar
|
|
13
|
Gurtan AM and Sharp PA: The role of miRnAs
in regulating gene expression networks. J Mol Biol. 425:3582–3600.
2013. View Article : Google Scholar
|
|
14
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar
|
|
15
|
Mendell JT: MicroRNAs: Critical regulators
of development, cellular physiology and malignancy. Cell Cycle.
4:1179–1184. 2005. View Article : Google Scholar
|
|
16
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar
|
|
17
|
Tiscornia G and Izpisúa Belmonte JC:
MicroRNAs in embryonic stem cell function and fate. Genes Dev.
24:2732–2741. 2010. View Article : Google Scholar
|
|
18
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar
|
|
19
|
Ping W, Gao Y, Fan X, Li W, Deng Y and Fu
X: MiR-181a contributes gefitinib resistance in non-small cell lung
cancer cells by targeting GAS7. Biochem Biophys Res Commun.
495:2482–2489. 2018. View Article : Google Scholar
|
|
20
|
Gartel AL and Kandel ES: miRNAs: Little
known mediators of oncogenesis. Semin Cancer Biol. 18:103–110.
2008. View Article : Google Scholar
|
|
21
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar
|
|
22
|
Negrini M, Nicoloso MS and Calin GA:
MicroRNAs and cancer–new paradigms in molecular oncology. Curr Opin
Cell Biol. 21:470–479. 2009. View Article : Google Scholar
|
|
23
|
Spizzo R, Nicoloso MS, Croce CM and Calin
GA: SnapShot: microRNAs in cancer. Cell. 137:586–586.e581. 2009.
View Article : Google Scholar
|
|
24
|
Voorhoeve PM: MicroRNAs: Oncogenes, tumor
suppressors or master regulators of cancer heterogeneity. Biochim
Biophys Acta. 1805.72–86. 2010.
|
|
25
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar
|
|
26
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
27
|
Hammond SM: MicroRNAs as tumor
suppressors. Nat Genet. 39:582–583. 2007. View Article : Google Scholar
|
|
28
|
Baraniskin A, Chomiak M, Ahle G, Gress T,
Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U and
Schmiegel W: MicroRNA-30c as a novel diagnostic biomarker for
primary and secondary B-cell lymphoma of the CNS. J Neurooncol.
137:463–468. 2018. View Article : Google Scholar
|
|
29
|
Li C, Zheng X, Li W, Bai F, Lyu J and Meng
QH: Serum miR-486-5p as a diagnostic marker in cervical cancer:
With investigation of potential mechanisms. BMC Cancer. 18:612018.
View Article : Google Scholar
|
|
30
|
Yao XD, Li P and Wang JS: MicroRNA
differential expression spectrum and microRNA-125a-5p inhibition of
laryngeal cancer cell proliferation. Exp Ther Med. 14:1699–1705.
2017. View Article : Google Scholar
|
|
31
|
Li G, Zhang W, Gong L and Huang X:
MicroRNA-125a-5p inhibits cell proliferation and induces apoptosis
in hepatitis B virus-related hepatocellular carcinoma by
downregulation of ErbB3. Oncol Res. 2017.
|
|
32
|
Coppola N, de Stefano G, Panella M,
Onorato L, Iodice V, Minichini C, Mosca N, Desiato L, Farella N,
Starace M, et al: Lowered expression of microRNA-125a-5p in human
hepatocellular carcinoma and up-regulation of its oncogenic targets
sirtuin-7, matrix metalloproteinase-11, and c-Raf. Oncotarget.
8:25289–25299. 2017. View Article : Google Scholar
|
|
33
|
Potenza N, Mosca N, Zappavigna S,
Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P,
Caraglia M, et al: MicroRNA-125a-5p is a downstream effector of
sorafenib in its antiproliferative activity toward human
hepatocellular carcinoma cells. J Cell Physiol. 232:1907–1913.
2017. View Article : Google Scholar
|
|
34
|
Zhong L, Sun S, Shi J, Cao F, Han X and
Chen Z: MicroRNA-125a-5p plays a role as a tumor suppressor in lung
carcinoma cells by directly targeting STAT3. Tumour Biol.
39:10104283176975792017. View Article : Google Scholar
|
|
35
|
Fu Y and Cao F: MicroRNA-125a-5p regulates
cancer cell proliferation and migration through NAIF1 in prostate
carcinoma. OncoTargets Ther. 8:3827–3835. 2015. View Article : Google Scholar
|
|
36
|
Zhang Y, Xue C, Zhu X, Zhu X, Xian H and
Huang Z: Suppression of microRNA-125a-5p upregulates the TAZ-EGFR
signaling pathway and promotes retinoblastoma proliferation. Cell
Signal. 28:850–860. 2016. View Article : Google Scholar
|
|
37
|
Qin X, Wan Y, Wang S and Xue M:
MicroRNA-125a-5p modulates human cervical carcinoma proliferation
and migration by targeting ABL2. Drug Des Devel Ther. 10:71–79.
2015.
|
|
38
|
Chen J, Chen Y and Chen Z: MiR-125a/b
regulates the activation of cancer stem cells in
paclitaxel-resistant colon cancer. Cancer Invest. 31:17–23. 2013.
View Article : Google Scholar
|
|
39
|
Kishimoto T: IL-6: From its discovery to
clinical applications. Int Immunol. 22:347–352. 2010. View Article : Google Scholar
|
|
40
|
Lu Z, Liu H, Xue L, Xu P, Gong T and Hou
G: An activated Notch1 signaling pathway inhibits cell
proliferation and induces apoptosis in human esophageal squamous
cell carcinoma cell line EC9706. Int J Oncol. 32:643–651. 2008.
|
|
41
|
Zafar S, Coates DE, Cullinan MP, Drummond
BK, Milne T and Seymour GJ: Effects of zoledronic acid and
geranylgeraniol on the cellular behaviour and gene expression of
primary human alveolar osteoblasts. Clin Oral Investig.
20:2023–2035. 2016. View Article : Google Scholar
|
|
42
|
Nana-Sinkam SP and Croce CM: MicroRNA
regulation of tumorigenesis, cancer progression and interpatient
heterogeneity: Towards clinical use. Genome Biol. 15:4452014.
View Article : Google Scholar
|
|
43
|
Wang X, Ivan M and Hawkins SM: The role of
MicroRNA molecules and MicroRNA-regulating machinery in the
pathogenesis and progression of epithelial ovarian cancer. Gynecol
Oncol. 147:481–487. 2017. View Article : Google Scholar
|
|
44
|
Kim J, Yao F, Xiao Z, Sun Y and Ma L:
MicroRNAs and metastasis: Small RNAs play big roles. Cancer
Metastasis Rev. 37:5–15. 2018. View Article : Google Scholar
|
|
45
|
Pastorkova Z, Skarda J and Andel J: The
role of microRNA in metastatic processes of non-small cell lung
carcinoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
160:343–357. 2016. View Article : Google Scholar
|
|
46
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar
|
|
47
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar
|
|
48
|
Dorrance AM, Neviani P, Ferenchak GJ,
Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J
and Hill EB: Targeting leukemia stem cells in vivo with
antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia.
29:2143–2153. 2015. View Article : Google Scholar
|
|
49
|
Jiang X, Bugno J, Hu C, yang Y, Herold T,
Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, et al: Eradication
of acute myeloid leukemia with FLT3 ligand-targeted miR-150
nanoparticles. Cancer Res. 76:4470–4480. 2016. View Article : Google Scholar
|
|
50
|
Keklikoglou I, Hosaka K, Bender C, Bott A,
Koerner C, Mitra D, Will R, Woerner A, Muenstermann E and Wilhelm
H: MicroRNA-206 functions as a pleiotropic modulator of cell
proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene.
34:4867–4878. 2015. View Article : Google Scholar
|
|
51
|
Papaconstantinou IG, Lykoudis PM, Gazouli
M, Manta A, Polymeneas G and voros D: A review on the role of
microRNA in biology, diagnosis, and treatment of pancreatic
adenocarcinoma. Pancreas. 41:671–677. 2012. View Article : Google Scholar
|
|
52
|
Robb T, Reid G and Blenkiron C: Exploiting
microRNAs as cancer therapeutics. Target Oncol. 12:163–178. 2017.
View Article : Google Scholar
|
|
53
|
Li Z, Peng Z, Gu S, Zheng J, Feng D, Qin Q
and He J: Global analysis of miRNA-mRNA interaction network in
breast cancer with brain metastasis. Anticancer Res. 37:4455–4468.
2017.
|
|
54
|
Cora’ D, Re A, Caselle M and Bussolino F:
MicroRNA-mediated regulatory circuits: Outlook and perspectives.
Phys Biol. 14:0450012017. View Article : Google Scholar
|
|
55
|
Tao T, Shen Q, Luo J, Xu Y and Liang W:
MicroRNA-125a regulates cell proliferation via directly targeting
E2F2 in osteosarcoma. Cell Physiol Biochem. 43:768–774. 2017.
View Article : Google Scholar
|
|
56
|
Hsu YL, Hung JY, Chou SH, Huang MS, Tsai
MJ, Lin YS, Chiang Sy, Ho YW, Wu CY and Kuo PL: Angiomotin
decreases lung cancer progression by sequestering oncogenic yAP/TAZ
and decreasing Cyr61 expression. Oncogene. 34:4056–4068. 2015.
View Article : Google Scholar
|
|
57
|
Brusgard JL, Choe M, Chumsri S, Renoud K,
MacKerell AD Jr, Sudol M and Passaniti A: RUnX2 and TAZ-dependent
signaling pathways regulate soluble E-Cadherin levels and
tumorsphere formation in breast cancer cells. Oncotarget.
6:28132–28150. 2015. View Article : Google Scholar
|
|
58
|
Bai H, Zhou L, Wang C, Xu X, Jiang J, Qin
Y, Wang X, Zhao C and Shao S: Involvement of miR-125a in resistance
to daunorubicin by inhibiting apoptosis in leukemia cell lines.
Tumour Biol. 39:10104283176959642017. View Article : Google Scholar
|
|
59
|
Palma Flores C, García-Vázquez R, Gallardo
Rincón D, Ruiz-García E, Astudillo de la Vega H, Marchat LA,
Salinas Vera YM and López-Camarillo C: MicroRnAs driving invasion
and metastasis in ovarian cancer: Opportunities for translational
medicine (Review). Int J Oncol. 50:1461–1476. 2017. View Article : Google Scholar
|
|
60
|
Verma V and Lautenschlaeger T: MicroRNAs
in non-small cell lung cancer invasion and metastasis: From the
perspective of the radiation oncologist. Expert Rev Anticancer
Ther. 16:767–774. 2016. View Article : Google Scholar
|
|
61
|
Chan SH and Wang LH: Regulation of cancer
metastasis by microRNAs. J Biomed Sci. 22:92015. View Article : Google Scholar
|
|
62
|
Zhao X, Li X and Yuan H: microRNAs in
gastric cancer invasion and metastasis. Front Biosci. 18:803–810.
2013. View Article : Google Scholar
|
|
63
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar
|
|
64
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar
|
|
65
|
Chen W, Kong KK, Xu XK, Chen C, Li H, Wang
FY, Peng XF, Zhang Z, Li P and Li JL: Downregulation of miR-205 is
associated with glioblastoma cell migration, invasion, and the
epithelial-mesenchymal transition, by targeting ZEB1 via the
Akt/mTOR signaling pathway. Int J Oncol. 52:485–495. 2018.
|
|
66
|
Chen C, Yang Q, Wang D, Luo F, Liu X, Xue
J, yang P, Xu H, Lu J, Zhang A, et al: MicroRNA-191, regulated by
HIF-2α, is involved in EMT and acquisition of a stem cell-like
phenotype in arsenite-transformed human liver epithelial cells.
Toxicol In Vitro. 48:128–136. 2018. View Article : Google Scholar
|
|
67
|
Huang J, He Y, Mcleod HL, Xie Y, Xiao D,
Hu H, Chen P, Shen L, Zeng S and Yin X: miR-302b inhibits
tumorigenesis by targeting EphA2 via Wnt/β-catenin/EMT signaling
cascade in gastric cancer. BMC Cancer. 17:8862017. View Article : Google Scholar
|
|
68
|
Xu X, Cao L, Zhang Y, Lian H, Sun Z and
Cui Y: MicroRNA-1246 inhibits cell invasion and epithelial
mesenchymal transition process by targeting CXCR4 in lung cancer
cells. Cancer Biomark. 21:251–260. 2018. View Article : Google Scholar
|
|
69
|
Berman M, Mattheolabakis G, Suresh M and
Amiji M: Reversing epigenetic mechanisms of drug resistance in
solid tumors using targeted microRNA delivery. Expert Opin Drug
Deliv. 13:987–998. 2016. View Article : Google Scholar
|
|
70
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRnA-200a confers chemoresistance by antagonizing
TP53inP1 and yAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar
|
|
71
|
Xiong J, Wang D, Wei A, Ke N, Wang Y, Tang
J, He S, Hu W and Liu X: MicroRNA-410-3p attenuates gemcitabine
resistance in pancreatic ductal adenocarcinoma by inhibiting
HMGB1-mediated autophagy. Oncotarget. 8:107500–107512. 2017.
View Article : Google Scholar
|
|
72
|
Leivonen SK, Icay K, Jäntti K, Siren I,
Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ and
d’Amore F: MicroRNAs regulate key cell survival pathways and
mediate chemosensitivity during progression of diffuse large B-cell
lymphoma. Blood Cancer J. 7:6542017. View Article : Google Scholar
|
|
73
|
Gabra MM and Salmena L: microRNAs and
acute myeloid leukemia chemoresistance: A mechanistic overview.
Front Oncol. 7:2552017. View Article : Google Scholar
|
|
74
|
Yang RM, Zhan M, Xu SW, Long MM, Yang LH,
Chen W, Huang S, Liu Q, Zhou J, Zhu J, et al: miR-3656 expression
enhances the chemosensitivity of pancreatic cancer to gemcitabine
through modulation of the RHOF/EMT axis. Cell Death Dis.
8:e31292017. View Article : Google Scholar
|
|
75
|
Nishida N, Mimori K, Fabbri M, Yokobori T,
Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M:
MicroRNA-125a-5p is an independent prognostic factor in gastric
cancer and inhibits the proliferation of human gastric cancer cells
in combination with trastuzumab. Clin Cancer Res. 17:2725–2733.
2011. View Article : Google Scholar
|
|
76
|
Moody HL, Lind MJ and Maher SG:
MicroRNA-31 regulates chemosensitivity in malignant pleural
mesothelioma. Mol Ther Nucleic Acids. 8:317–329. 2017. View Article : Google Scholar
|
|
77
|
Ara T, Nakata R, Sheard MA, Shimada H,
Buettner R, Groshen SG, Ji L, Yu H, Jove R and Seeger RC: Critical
role of STAT3 in IL-6-mediated drug resistance in human
neuroblastoma. Cancer Res. 73:3852–3864. 2013. View Article : Google Scholar
|
|
78
|
Suh YA, Jo SY, Lee HY and Lee C:
Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor
tyrosine kinases by apigenin circumvent taxol resistance in ovarian
cancer cells. Int J Oncol. 46:1405–1411. 2015. View Article : Google Scholar
|
|
79
|
Garcia R, Bowman TL, Niu G, Yu H, Minton
S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R and Parsons S:
Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar
|
|
80
|
Epling-Burnette PK, Liu JH,
Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang
JM, Yang-Yen HF and Karras J: Inhibition of STAT3 signaling leads
to apoptosis of leukemic large granular lymphocytes and decreased
Mcl-1 expression. J Clin Invest. 107:351–362. 2001. View Article : Google Scholar
|
|
81
|
Huang W, Dong Z, Chen Y, Wang F, Wang CJ,
Peng H, He Y, Hangoc G, Pollok K and Sandusky G: Small-molecule
inhibitors targeting the DNA-binding domain of STAT3 suppress tumor
growth, metastasis and STAT3 target gene expression in vivo.
Oncogene. 35:8022016. View Article : Google Scholar
|
